Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma

Inclusion Criteria:

* Pathologically confirmed mantle cell lymphoma
* Relapse or progression after 1-3 lines of previous chemotherapy with or without immunologic agents
* ECOG performance status 2 or less
* Adequate hematologic, hepatic, and renal function i. White blood cells ≥ 3,000 /ul ii. Absolute neutrophil count ≥ 1,000 /ul iii. Platelets ≥ 50,000 /ul iv. Hemoglobin ≥ 9.0 g/dL v. Total bilirubin \< 2 times upper limit of normal vi. AST, ALT \< 2.5 times upper limit of normal vii. Serum creatinine \< 1.5 times upper limit of normal

Exclusion Criteria:

* Previously treated with 4 or more lines of chemotherapy with or without immunologic agents
* Previously treated with bortezomib
* Treated with a cytarabine-containing regimen as the last line and within 6 months before registration
* Other cancer diagnosed within 5 years before registration
* Uncontrolled symptomatic CNS involvement of mantle cell lymphoma
* Uncontrolled systemic infection
* Inherited immunodeficiency disease or AIDS
* Pregnancy
* Breast-feeding
* Peripheral neuropathy of grade 3 or higher
* Other health conditions considered to be inappropriate for this trial in the primary physician's opinion